Tetrahydropalmatine

Tetrahydropalmatine, an active component isolated from corydalis, possesses analgesic effects. Tetrahydropalmatine acts through inhibition of amygdaloid release of dopamine to inhibit an epileptic attack in rats.

Product information

CAS Number: 2934-97-6

Molecular Weight: 355.43

Formula: C21H25NO4

Synonym:

DL-Tetrahydropalmatine

Chemical Name: 2, 3, 9, 10-tetramethoxy-6, 8, 13, 13a-tetrahydro-5H-isoquinolino[2, 1-b]isoquinoline

Smiles: COC1=CC2C3CC4=CC=C(OC)C(OC)=C4CN3CCC=2C=C1OC

InChiKey: AEQDJSLRWYMAQI-UHFFFAOYSA-N

InChi: InChI=1S/C21H25NO4/c1-23-18-6-5-13-9-17-15-11-20(25-3)19(24-2)10-14(15)7-8-22(17)12-16(13)21(18)26-4/h5-6,10-11,17H,7-9,12H2,1-4H3

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 6.67 mg/mL (18.77 mM; Need ultrasonic)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥360 days if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vivo:

Tetrahydropalmatine (THP), an active component isolated from corydalis (a Chinese herbal medicine), possesses analgesic effects. Picrotoxin treatment alone has a significant effect on the following activity measure: there is an increase in horizontal motion time (HMT), vertical motion time (VMT), clockwise turnings (CT), anticlockwise turning (ACT) and a decrease in freezing time (FT). Tetrahydropalmatine treatment alone causes a decrease in HMT, VMT and total distance traveled (TDT), but an increase in FT. Pretreatment of rats with an i.p. dose of 10 mg/kg or 15 mg/kg of Tetrahydropalmatine significantly attenuates the Picrotoxin-induced enhancement in HMT, VMT, CT, ACT and TDT, as well as reduction in FT. Another 48 rats under urethane anesthesia are randomly divided into six groups, each of eight rats. The s.c. injection of Picrotoxin causes an increase in amygdaloid release of dopamine (DA), while i.p. injection of Tetrahydropalmatine at 10 mg/kg has an insignificant effect on amygdaloid release of DA. Again, the Picrotoxin-induced increase in amygdaloid release of DA is significantly attenuated by pretreatment with Tetrahydropalmatine. The Picrotoxin-induced augmented amygdaloid release of DA is almost completely abolished by pretreatment with Tetrahydropalmatine 30 min before s.c. injection of Picrotoxin.

References:

1. Chang CK, et al. DL-Tetrahydropalmatine may act through inhibition of amygdaloid release of dopamine to inhibit an epileptic attack in rats. Neurosci Lett. 2001 Jul 20;307(3):163-6.

Products are for research use only. Not for human use.